E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the change in EPC count in kidney graft recipients converted from cyclosporine to tacrolimus
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the change in cystatin C as measure of renal function in kidney graft recipients converted from cyclosporine to tacrolimus
To determine the effect of tacrolimus on humoral alloreactivity in long-term kidney graft recipients |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Patient is recipient of a deceased or living donor renal transplant (including re-transplants) 2. Patient was ≥18 years of age at the time of transplantation. 3. Patient is at least 6 months post-transplant. 4. Patient is on a cyclosporine-based immunosuppression regimen in combination with/without MMF and/or steroids at study entry. 5. Patient has a functioning renal allograft and an estimated GFR ≥30 mL/min/1.73m2 within four weeks prior to study entry. 6. Patient has a stable graft function without biopsy proven acute rejection episode within 3 months prior to study entry. 7. Patient has not experienced a cardiovascular event (e.g. myocardial infarction, stroke, percutaneous angioplasty, bypass surgery,..) within 3 months prior to study entry. 8. Patient has been fully informed and has given written informed consent according to ICH-GCP. Patient unable to write and/or read but who fully understands the oral information given by the investigator (or nominated representative) has given oral informed consent witnessed in writing by an independent person. 9. Females are not pregnant and agree to practice effective birth control while receiving immunosuppressant medication. 10. Patient has indications for conversion at the investigators discretion or is suffering from cyclosporine associated side effects like hypertension (≥130 and/or ≥80 mm Hg, with or without antihypertensive therapy), hyperlipidemia (LDL-cholesterol ≥ 100 mg/dl or triglycerides≥200 mg/dl and non-HDL-cholesterol ≥130 mg/dl) or cosmetic side effects.
|
|
E.4 | Principal exclusion criteria |
1. Patient is recipient of a solid organ transplant other than the kidney. 2. Patient has recurrence of primary renal disease, or de novo renal disease. 3. Patient is pregnant or lactating. 4. Patient had a known or suspected malignancy (except for treated squamous and basal cell skin cancers) <5 years before study entry or a history of post-transplant lymphoproliferative disease (PTLD). 5. Patient has known hypersensitivity to tacrolimus, or any of the recipients of the drug.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The sample size calculation is based on the results of a pilot study of 90 stable kidney graft recipients, where the distribution of EPC counts was found to be strongly skewed to the right. Therefore, we used logarithmical transformation to normalize the distribution of the data. The mean lnEPC count was 3.6 ± 1.0 per high power field. Assuming an increase of 15% in lnEPC count after conversion from cyclosporine to tacrolimus (asimilar effect was observed for statin users versus non-users in our pilot study) that persists for at least 2 years, and using a 2:1 randomization, 41 patients are needed in the cyclosporine group, and 82 in the tacrolimus group (type I error 0.05, power 80%). Accounting for an annual rate of graft loss and death of 5%, and an annual rate of drop out related to further changes in the immunosuppressive protocol of 5%, 49 patients are needed for the cyclosporine group, and 99 patients are needed for the tacrolimus group. The paired t-test will be used to compare lnEPC between the treatment groups at 3, 12 and 24 months post-randomization. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |